283PD201 A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease

NCT05348785

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease

Associated Conditions

Parkinsons

Principal Investigator

Sponsor

Biogen

You may be eligible to take part in the study because you have Parkinson’s Disease (PD). Only people who have been diagnosed with PD in the past 2 years and who are within the ages of 30 to 80 years can take part in the study. Also, a small number of participants may be taking a stable dose of medication (levodopa or monoamine oxidase-B inhibitors) for the management of PD symptoms.

This study is currently enrolling.